Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06455059 · ClinicalTrials.gov registry record · Phase 3

Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia

A Phase 3 study of Hypochondroplasia, sponsored by BioMarin Pharmaceutical.

Active
Registry status
Phase 3
Development phase
80
Enrollment target
20
Study locations

NCT06455059 is a Phase 3 study of Hypochondroplasia that is active but no longer recruiting, run by BioMarin Pharmaceutical. The registered enrollment target is 80 participants, below the 175-participant average among 4 other Hypochondroplasia trials with a reported enrollment target (54% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06455059, a Phase 3 study of Hypochondroplasia, is active but no longer recruiting, sponsored by BioMarin Pharmaceutical.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
80 participants
Enrollment target
20
Study locations

Study Summary

The intent and design of this Phase 3 study is to assess vosoritide as a therapeutic option for the treatment of children with hypochondroplasia (HCH).

Conditions Studied

Hypochondroplasia

Interventions

  • DRUG Placebo
  • DRUG Vosoritide

Study Locations (20)

Other

  • Hospices Civils de Lyon - Hopital Femme Mere Enfant - Lyon
  • Hopital de la Timone - Marseille
  • Hopital Necker-Enfants Malade - Paris
  • CHU de Toulouse - Toulouse
  • Uniklinik Koln - Cologne
  • Univeristatskinderklinik Magdeburg - Magdeburg
  • Instituto Giannina Gaslini - Genoa
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Rome
  • Ospedale Pediatrico Bambino Gesu - Rome
  • Osaka University Hosptial - Osaka
  • Tokushima University Hospital - Tokushima
  • Institute of Science Tokyo Hospital - Tokyo

Delaware

  • Nemours Alfred I. DuPont Hospital for Children - Wilmington

District of Columbia

  • Children's National Medical Center - Washington D.C.

Illinois

  • Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago

Wisconsin

  • Medical College of Wisconsin - Milwaukee

Victoria

  • Murdoch Children's Research Institute - Parkville

Alberta

  • University of Alberta Stollery Children's Hospital - Edmonton

Ontario

  • SickKids - The Hospital for Sick Children - Toronto

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2024-06-17
Est. Completion 2026-08-01
Phase Phase 3

Sponsor

BioMarin Pharmaceutical

80 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06455059

The ClinicalTrials.gov registry entry for NCT06455059 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 175-participant average among 4 other Hypochondroplasia trials with a reported enrollment target (54% lower). The listed sponsor is BioMarin Pharmaceutical, which has 80 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hypochondroplasia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06455059 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, Delaware, District of Columbia.

Frequently Asked Questions

What is clinical trial NCT06455059 about?

NCT06455059 is a clinical study titled "Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia". The intent and design of this Phase 3 study is to assess vosoritide as a therapeutic option for the treatment of children with hypochondroplasia (HCH).

What is the current status of trial NCT06455059?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 80 participants. The study started on 2024-06-17. Estimated completion is 2026-08-01.

What conditions does trial NCT06455059 study?

This clinical trial studies the following conditions: Hypochondroplasia.

What interventions are being tested in trial NCT06455059?

The interventions under investigation include: Placebo (DRUG), Vosoritide (DRUG).

Who is sponsoring clinical trial NCT06455059?

This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06455059 being conducted?

This trial has 20 study locations across Delaware, District of Columbia, Illinois, Wisconsin, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hypochondroplasia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hypochondroplasia

All registered trials for this condition

Delaware

All trials with a study site in Delaware

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.